LabGenius 🇬🇧

Series B

EVA ML-driven, robotic antibody discovery platform for selectivity-enhanced antibodies against solid tumours. London.

About LabGenius

LabGenius Therapeutics has developed the EVA™ platform, an automated discovery engine that utilizes artificial intelligence, robotic automation, and synthetic biology to identify and optimize complex therapeutic antibodies. This platform is designed to be modality and format-agnostic, focusing on selectivity-enhanced antibodies aimed at treating solid tumors.

LabGenius is a UK-based company founded in 2012, now around 63 people. FundFinder classes it as DeepTech & Space.

Founded by James Field (CEO & Founder; previously Zouk Capital LLP; Imperial College London), Rhys Algar (CTO & Co-founder; previously Commerzbank AG; Imperial College London).

Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.

Want the latest on LabGenius? Our research agent pulls the current description, latest round and full investor base from public sources (about a minute).

Series B · Jul 2025

InvestorsLCLux Capital

Lux Capital — New York-based deep-tech VC investing from seed to growth at the intersection of science, technology and national security: AI, advanced manufacturing, energy, biotech and defence. · cheques £1M – £20M

Raising your own round? See which European funds fit →